Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Prostatic Neoplasms 19Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 2Glioma 2Glioblastoma 2Brain Neoplasms 2Thromboembolism 1Solid Tumors 1Oligodendroglioma 1Neuroblastoma 1Lymphoma, Follicular 1Leukemia, Myeloid, Chronic-Phase 1Granulosa Cell Tumor 1Castration-resistant Prostate Cancer 1Breast Neoplasms 1Astrocytoma 1Advanced Cancer 1

Interventions

Sunitinib 4Cyclophosphamide 4Capecitabine 4Bevacizumab 4pazopanib 3Topotecan 3Paclitaxel 3Docetaxel 3Carboplatin 3temsirolimus 2liposomal doxorubicin 2fludarabine 2Sorafenib 2Panobinostat 2NVP-BKM120 2Lapatinib 2Irinotecan 2Immune Checkpoint Inhibitors 2Gemcitabine 2Everolimus 2Erlotinib Hydrochloride 2Doxorubicin 2Bortezomib 2vadimezan 1spartalizumab 1somatostatin receptor 2 1selinexor 1selicrelumab 1perifosine 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Solid Tumors × Ketoconazole × Clear all
NCT00697437 2013-12-10

Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel

National University Hospital, Singapore

Phase 2 Completed
10 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡